肾内科指南

订阅

MedSci主页 / 所有栏目 / 肾内科指南

肾病患者静脉注射碘对比剂应用专家共识

2021-06-15 中华医学会放射学分会 中华放射学杂志.2021.55(6):580-590.

急性肾损伤

随着对碘对比剂与肾损伤关系的深入研究和认知，尤其是在静脉注射碘对比剂的情况下，对比剂后急性肾损伤（PC-AKI）的概念已经取代对比剂肾病这一术语。国际上多个组织和学会据此更新了碘对比剂使用指南或共识。

中文标题：

肾病患者静脉注射碘对比剂应用专家共识

发布机构：

中华医学会放射学分会

发布日期：

2021-06-15

简要介绍：

随着对碘对比剂与肾损伤关系的深入研究和认知，尤其是在静脉注射碘对比剂的情况下，对比剂后急性肾损伤（PC-AKI）的概念已经取代对比剂肾病这一术语。国际上多个组织和学会据此更新了碘对比剂使用指南或共识。为普及和规范我国肾病患者静脉注射碘对比剂的应用，中华医学会放射学分会质量控制与安全管理专业委员会组织专家参阅大量文献并结合我国的临床实践，经反复讨论并达成以下共识，包括PC-AKI的术语、危险因素及预防方案等。

下载附件：
点击下载

(因为版权问题，不支持下载)

评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1072846, encodeId=0a8f10e2846b0, content=实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce295587728, createdName=ms6000000414198546, createdTime=Mon Nov 22 14:33:51 CST 2021, time=2021-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069089, encodeId=8e67106908951, content=实用！！！！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=adb44137078, createdName=13c49547m62暂无昵称, createdTime=Wed Nov 10 21:24:53 CST 2021, time=2021-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063853, encodeId=f91c10638530a, content=实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=df895647787, createdName=ms2000000593713261, createdTime=Mon Oct 25 19:52:52 CST 2021, time=2021-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1011740, encodeId=749d1011e402d, content=挺实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=09d55447382, createdName=ms2000002074214464, createdTime=Thu Aug 26 16:56:19 CST 2021, time=2021-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1010926, encodeId=e0b710109261a, content=有临床意义, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7d25091682, createdName=145d4c03m99暂无昵称, createdTime=Tue Aug 24 11:22:48 CST 2021, time=2021-08-24, status=1, ipAttribution=)]
    2021-11-22 ms6000000414198546

    实用

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1072846, encodeId=0a8f10e2846b0, content=实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce295587728, createdName=ms6000000414198546, createdTime=Mon Nov 22 14:33:51 CST 2021, time=2021-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069089, encodeId=8e67106908951, content=实用！！！！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=adb44137078, createdName=13c49547m62暂无昵称, createdTime=Wed Nov 10 21:24:53 CST 2021, time=2021-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063853, encodeId=f91c10638530a, content=实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=df895647787, createdName=ms2000000593713261, createdTime=Mon Oct 25 19:52:52 CST 2021, time=2021-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1011740, encodeId=749d1011e402d, content=挺实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=09d55447382, createdName=ms2000002074214464, createdTime=Thu Aug 26 16:56:19 CST 2021, time=2021-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1010926, encodeId=e0b710109261a, content=有临床意义, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7d25091682, createdName=145d4c03m99暂无昵称, createdTime=Tue Aug 24 11:22:48 CST 2021, time=2021-08-24, status=1, ipAttribution=)]
    2021-11-10 13c49547m62暂无昵称

    实用！！！！

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1072846, encodeId=0a8f10e2846b0, content=实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce295587728, createdName=ms6000000414198546, createdTime=Mon Nov 22 14:33:51 CST 2021, time=2021-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069089, encodeId=8e67106908951, content=实用！！！！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=adb44137078, createdName=13c49547m62暂无昵称, createdTime=Wed Nov 10 21:24:53 CST 2021, time=2021-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063853, encodeId=f91c10638530a, content=实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=df895647787, createdName=ms2000000593713261, createdTime=Mon Oct 25 19:52:52 CST 2021, time=2021-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1011740, encodeId=749d1011e402d, content=挺实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=09d55447382, createdName=ms2000002074214464, createdTime=Thu Aug 26 16:56:19 CST 2021, time=2021-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1010926, encodeId=e0b710109261a, content=有临床意义, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7d25091682, createdName=145d4c03m99暂无昵称, createdTime=Tue Aug 24 11:22:48 CST 2021, time=2021-08-24, status=1, ipAttribution=)]
    2021-10-25 ms2000000593713261

    实用

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1072846, encodeId=0a8f10e2846b0, content=实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce295587728, createdName=ms6000000414198546, createdTime=Mon Nov 22 14:33:51 CST 2021, time=2021-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069089, encodeId=8e67106908951, content=实用！！！！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=adb44137078, createdName=13c49547m62暂无昵称, createdTime=Wed Nov 10 21:24:53 CST 2021, time=2021-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063853, encodeId=f91c10638530a, content=实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=df895647787, createdName=ms2000000593713261, createdTime=Mon Oct 25 19:52:52 CST 2021, time=2021-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1011740, encodeId=749d1011e402d, content=挺实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=09d55447382, createdName=ms2000002074214464, createdTime=Thu Aug 26 16:56:19 CST 2021, time=2021-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1010926, encodeId=e0b710109261a, content=有临床意义, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7d25091682, createdName=145d4c03m99暂无昵称, createdTime=Tue Aug 24 11:22:48 CST 2021, time=2021-08-24, status=1, ipAttribution=)]
    2021-08-26 ms2000002074214464

    挺实用

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1072846, encodeId=0a8f10e2846b0, content=实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce295587728, createdName=ms6000000414198546, createdTime=Mon Nov 22 14:33:51 CST 2021, time=2021-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069089, encodeId=8e67106908951, content=实用！！！！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=adb44137078, createdName=13c49547m62暂无昵称, createdTime=Wed Nov 10 21:24:53 CST 2021, time=2021-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063853, encodeId=f91c10638530a, content=实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=df895647787, createdName=ms2000000593713261, createdTime=Mon Oct 25 19:52:52 CST 2021, time=2021-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1011740, encodeId=749d1011e402d, content=挺实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=09d55447382, createdName=ms2000002074214464, createdTime=Thu Aug 26 16:56:19 CST 2021, time=2021-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1010926, encodeId=e0b710109261a, content=有临床意义, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7d25091682, createdName=145d4c03m99暂无昵称, createdTime=Tue Aug 24 11:22:48 CST 2021, time=2021-08-24, status=1, ipAttribution=)]
    2021-08-24 145d4c03m99暂无昵称

    有临床意义

    0

相关指南

2021 ADQI/POQI共识：成人非心脏手术后急性肾损伤

暂未更新 · 2021-05-11

NICE指南：急性肾损伤的预防，检测和治疗 2019

国家卫生和护理研究所（NICE） · 2019-12-26

急性疾病质量倡议共识会议对急性肾损伤生物标志物的建议：共识声明

暂未更新 · 2020-10-05

新型冠状病毒感染合并急性肾损伤诊治专家共识

中华医学会肾脏病学分会 · 2020-03-30

2017 共识指南：应用羧肽酶治疗高剂量甲氨蝶呤引起急性肾损伤以及甲氨蝶呤清除延迟患者

国外肿瘤科相关专家小组（统称） · 2017-10-27

2016 SIN立场声明：体外轻链去除技术治疗多发性骨髓瘤导致的急性肾损伤

意大利肾病学会(SIN,Italian Society of Nephrology) · 2016-10-18

拓展阅读

2010急性肾损伤成像的良好实践建议

美国影像局(NIB,National Imaging Board) · 2010-01-01

2011RA临床实践指南：急性肾损伤

英国肾脏病协会(RA,The Renal Association) · 2010-05-26

2011RA临床实践指南：急性肾损伤

英国肾脏病协会(RA,The Renal Association) · 2011-01-01

2012KDIGO急性肾损伤（AKI）临床指南

改善全球肾脏病预后组织(KDIGO,Kidney Disease: Improving Global Outcomes) · 2012-03-01

2013 挤压综合征急性肾损伤诊治的专家共识

挤压综合征急性肾损伤诊治协助组 · 2013-05-07

2013 NICE 169 急性肾损伤

英国国家卫生与临床优化研究所(NICE,National Institute for Health and Clinical Excellence) · 2013-08-28